The doping case of tennis star Jannik Sinner, currently ranked world number one, is set to extend into the new year, as the Court of Arbitration for Sport (CAS) is unlikely to issue a ruling before 2024. This announcement comes from the World Anti-Doping Agency (WADA), which confirmed the delay in a recent interview. WADA's Director General, Olivier Niggli, stated, "There will be nothing by the end of the year," signaling that the issue will not be resolved in the immediate future.
Sinner, 23, made headlines earlier this year after testing positive for clostebol, a banned anabolic steroid, in two separate tests conducted in March. However, following an investigation, the Italian was cleared of any wrongdoing. An independent tribunal convened in late August, at the request of the International Tennis Integrity Agency (ITIA), ruled that Sinner "bears no fault or negligence" in the matter. This verdict allowed him to continue competing on the ATP tour, where he had already captured titles at the Australian Open and the US Open.
The tribunal's ruling was based on Sinner's explanation that the drug entered his system unintentionally. He claimed that his physiotherapist had used a spray containing clostebol to treat a minor cut, which led to the contamination. This explanation was accepted by the ITIA, which ultimately cleared the player of any intentional violation.
Despite this, WADA has appealed the ruling, seeking to impose a ban of up to two years on the Italian. The core issue, according to Niggli, revolves around Sinner’s responsibility regarding the actions of his entourage. "It was considered in the decision that there was no fault on the part of Sinner. Our position is that there is still a responsibility of the athlete in relation to his entourage," Niggli explained. WADA does not dispute the possibility of contamination but argues that the application of anti-doping regulations in this case does not align with existing case law.
This appeal has raised broader concerns within the tennis community, especially regarding the timeliness and transparency of such cases. The ITIA came under criticism for the delayed public disclosure of Sinner’s and Polish tennis star Iga Świątek’s positive tests. While Świątek accepted a one-month suspension after testing positive for the heart medication trimetazidine, she, like Sinner, faced questions over the handling of her case.
Niggli, however, defended the approach, emphasizing the importance of protecting athletes’ reputations. "Personally, I think that protecting an athlete’s reputation should be our first concern," he said. "We live in a world where social media can destroy a reputation in the blink of an eye."
